Unfortunately, we don't support Internet Explorer anymore as it has been replaced by Microsoft Edge. Please try using Edge or an alternative modern browser for the best experience.
Dr. Christina Trojel-Hansen is currently serving as founding CEO of a regenerative medicine newco focusing on in situ cell programming strategies for reversing brain aging and disease, and co-founding advisor for a neuroinflammation focused newco. Dr.Trojel was previously founding CEO of Oscine Therapeutics, a CNS cell therapy firm that got acquired by Sana Biotechnology in 2020. Dr. Trojel additionally co-founded Pretzel Therapeutics with ARCH Venture Partners and Tune Therapeutics with Emerson Collective. Dr. Trojel also serves as Adjunct Assistant Professor at the University of Rochester Medical Center, Center for Translational Neuromedicine, and is EIR with ARCH. Dr. Trojel was previously at Novo Holdings in Denmark, where she was involved with both investments and grant programs.
Dr. Trojel has a background in the field of nanobiotechnology and cancer epigenetics. She completed her post-doctoral training at Institute Gustave Roussy (INSERM). Christina holds a PhD from University of California, Berkeley and University of Copenhagen, and an MSc from BRIC and iNANO at University of Aarhus, Denmark.
Christina has received a number of recognitions, most recently she was selected for Endpoints’ 20 under 40’ next generation biotech leaders (2021)
